PTGX Q3 2018 Earnings — Protagonist Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

PTGXProtagonist Therapeutics, Inc.

$6B

Q3 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$6M-30.3% YoY

Gross Profit

$6M100.0% margin

Operating Income

-$9M-153.5% margin

Net Income

-$9M-142.8% margin

EPS (Diluted)

$-0.38

QoQ Revenue Growth

-47.6%

Cash Flow

Operating Cash Flow

-$9M

Free Cash Flow

-$9M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$149M

Total Liabilities

$25M

Stockholders' Equity

$124M

Cash & Equivalents

$87M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$6M	$9M	-30.3%
Gross Profit	$6M	$9M	-30.3%
Operating Income	-$9M	-$5M	-88.5%
Net Income	-$9M	-$5M	-81.0%

Revenue Segments

License And Collaborative Revenue

$6M100%